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ETIn conclusion, this study demonstrates that it is possible
o treat patients with ABF using an endovascular approach
nd that the results compare favorably with open surgical
epair. Patients tolerated the procedure well, and hemoptysis
esolved in all 7 patients. There were no deaths, no episodes
f paraplegia, and no endoprosthesis infections. All patients
re still alive and there have been no reinterventions. Care-
ul preoperative planning is essential for optimal results
hen patients are being considered for endovascular repair,
specially with regards to vascular access considerations. In
ur cohort, duration and type of postoperative antibiotics
oes not appear to correlate with freedom from graft infec-
ion. Although endovascular technologies are emerging for
he treatment of many types of aortic pathologies, signifi-
ant questions relating to this therapeutic modality are yet to
e resolved including long-term device durability, improved
ong-term patient outcomes, and economic concerns of in-
reased device cost and expenses related to long-term graft
urveillance with CT. Additional investigation and contin-
ed graft surveillance are critical to help determine the
uture role of endovascular technologies.
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iscussion
r Craig Miller (Stanford, Calif). Thank you, Dr Gelfand and Dr
awkins. Grayson, that was a very nice presentation that we’ve
ome to expect from you.
This is the third report from the Arizona Heart Institute on
ndovascular treatment of aortotracheal fistulas. Before you got
here, there was a report in 2002 with 2 cases. In your large total
xperience reported this year in the Annals you had 4, and now you
ave taken us up to 7. You pointed out in the paper that there are
6 cases in the literature and now with 3 more additional, so 39,
ith an overall mortality rate of 8%, which is pretty darn good
onsidering that a lot of these patients need reoperations and have
ad previous grafts and whatnot. I think that is very encouraging.
he question, therefore, is not can it be done. You and others and
e have shown that it can be done, but how effective and how
and Cardiovascular Surgery ● Volume 133, Number 5 1283
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1
ETurable is it for what can be a devastatingly bad situation? And
ere I think you have provided some very good news with your
ollow-up: 43 29 months going out to 6 years, no late deaths, no
ate infections. It’s almost too good to believe, but it is good news
nd it is very promising and we look forward to more follow-up.
I would like to turn to something that you’ve already broached
nd that’s the legal and the ethical issues at foot here. You’ve
hown us very clearly the amount of work that Dr Diethrich and
he institution had to go through to get a physician-sponsored
ndividual investigator device exemption (IDE) from the Food and
rug Administration. We have also done that, and that allowed
ou to treat these patients, who would otherwise not have qualified
or any of the commercial IDEs. There now are a couple high-risk
DEs that cover this but they are few in number. I want to caution
he audience that if you go home and try this, if you are Gore TAG
ertified, it is going to be off label for an aortobronchial or for an
ortoesophageal fistula or even a dissection. It is going to be off
abel, and you have to be very, very aware that if something
oesn’t go perfectly well, you don’t have a leg to stand on
edicolegally in court. The lawyers are out there just waiting for
his, and there have been all too many examples already—an
bdominal aortic stent graft or a home-brew stent graft or a
ommercial stent graft used for aortic dissection, for example—
here something bad happened, and you just don’t have a leg to
tand on legally unless you have an institutional physician-spon-
ored IDE like you do. That brings me to, what are you doing now?
s your physician-sponsored IDE still current, and do you enroll
hem in that today just to cover yourselves? That’s the first ques-
ion, easy one.
Dr G.H. Wheatley (Phoenix, Ariz). Yes. We applied for, and
uccessfully received, an extension and continuation of that pro-
ocol. Patients who are being treated with aneurysms were origi-
ally included in the protocol, but now that it is Food and Drug
dministration approved for aneurysms; those patients are not
nrolled in the protocol, and so the protocol now only includes
ff-label uses in the high-risk surgical patients.
Dr Miller. So right now, you are shut down until the Food and
rug Administration rules on your extension application?
Dr Wheatley. No, it’s been approved, and we have been
ontinuously enrolling patients without interruption.
Dr Miller. Oh, it’s been renewed and extended. Okay. So
ou’re being judicious and that’s important for those of you who
ight see one of these desperately ill patients roll in some Friday
ight, because even though you are trying to save their lives, the
state of the family may not see it that way later on.
Okay, 7 cases now. Three were aneurysms, 3 were false aneu-
ysms, and 1 traumatic case. Your slide—I’m glad you showed
hat happened to the sac with the serial CT scans thereafter. That
as one of my questions and that information I assume will now
e in the paper. You had 8 patients on that slide, not 7. Can you
xplain where that eighth flyer got in there? Second, could you
laborate on what happened with the patient with 1 traumatic tear,
ho had had a previous stent graft? Was it elsewhere? Was it your
lace? And why that 1 created the complication? And third, I was
little surprised to see that you did not have any giant aortic
enetrating ulcers, atherosclerotic ulcers, which can cause an aor-
otracheal fistula. Any comments there? t
284 The Journal of Thoracic and Cardiovascular Surgery ● MaDr Wheatley. Yes. Thank you, Dr Miller, for your comments
nd certainly thank you for your comments regarding the manu-
cript and we greatly appreciate your insight.
In terms of the eighth one, that was not included in the graph.
t was on the label but it wasn’t there. If you count the actual lines,
here were only 7. It was a benefit of PowerPoint presentations.
Interesting case, I agree. I think that we need to be very
ognizant, and this is 1 of the first that I have been aware of where
patient was 3 years out from a prior ELG repair of a transection.
his patient was badly injured. He had motor vehicle accident,
iver laceration, and brain injury and was hemodynamically unsta-
le, that’s why he was treated with an endoluminal graft, because
f his instability and very significant injury, but did well. Three
ears later he came back with an area distal to that ELG, which
as an ulcerative lesion—no real penetrating ulcer, but there is
ommunication right at the distal end of the graft, perhaps maybe
ecause the graft is eroding. The patient did not have aneurysmal
isease. Maybe there are some long-term consequences of the
LGs that we are not seeing, but certainly I think that this high-
ights that we need to be very scrupulous in following these
atients, and perhaps it may be a long-term complication of ELG
epair in traumatic transections.
Dr Miller. But it wasn’t frankly eroded through to the outside.
Dr Wheatley. No, there was just a communication there that
erhaps may have been related to the graft.
Dr Miller. And it probably wasn’t atherosclerotic disease be-
ause this patient sounds like the typical trauma victim—young,
ealthy, tiny normal aorta and no insurance, right?
Dr Wheatley. Yes, sir.
Dr Miller. You purposely covered the left subclavian once
ithout embolizing it or doing a transposition. You, of course, are
etting yourself up for a type 2 leak and we all know that. Some of
s have done it. No leak occurred in that patient. What is your
urrent practice? Do you leave a patent left subclavian transmitting
ndotension to the sac?
Dr Wheatley. We do. We just reported at (ISMICS) 2 weeks
go, our complete 360-patient experience with covering the left
ubclavian. We cover the left subclavian approximately a third of
he time and only needed a bypass in a few patients out of those
atients that had covered. If we do see a retrograde type 2 leak
rom the subclavian, we will then embolize it using a retrograde
pproach from the brachial, but we manage that usually expect-
ntly. We will usually see that if it is a type 2 endoleak, it is a
inor procedure to come back and embolize the subclavian. If
here is continued sac growth, it is something that we can always
o later, but it is not an emergency need to treat that.
Dr Miller. That’s a good answer and probably the right pos-
ure, but it is a vexing problem because of the strokes occurring
cutely when the left subclavian is covered. I won’t go off on a
angent to ask you how you decide when to revascularize it in
dvance and when not.
Finally, your topic is “Have we gone too far?” and you’re
ushing the envelope. Let me take you 1 step further. How many
ortoesophageal fistulas have you covered with a stent graft, which
e have done, but I think we are kidding ourselves and this is futile
herapy. What is your experience down in Phoenix?
Dr Wheatley. I agree and that’s why I did not include these inhe paper. It would be a natural fit to talk about aortoesophageal
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really don’t think that is a good approach, and that’s why I did not
reak these patients out, but really I don’t think that should be even
ried.
Dr Miller. Got reinfected and died like a dog run over in the
treet.
Dr Wheatley. Yes, sir.
Dr Miller. Yeah, I’m afraid we echo that. Thank you foroming to the Western Thoracic.
The Journal of ThoracicDr Wheatley. Thank you.
Dr Robert Cerfolio (Birmingham, Ala.). I had 2 questions but
e only have time for just 1. If you were going to cover a tracheal
stula with an aortic graft, do you now recommend that you put in
graft long enough that you go past or distal to the carina? My
oncern would be that the distal end of that stent is going to erode
nto either the left main stem or the carina unless you go past it. Is
his your recommendation now?Dr Wheatley. Yes.
and Cardiovascular Surgery ● Volume 133, Number 5 1285
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